Interestingly, HER2‐AAb levels were determined in 500 patients with invasive breast cancer in a previous study where 28 patients were administered adjuvant trastuzumab in combination with chemotherapy.11 This evidence concerns the gene ERBB2 and invasive breast carcinoma.